These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1200 related articles for article (PubMed ID: 34281566)

  • 1. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
    Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG PET using SUV
    Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
    BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review.
    Wang HH; Steffens EN; Kats-Ugurlu G; van Etten B; Burgerhof JGM; Hospers GAP; Plukker JTM
    Ann Surg Oncol; 2024 Jan; 31(1):433-451. PubMed ID: 37777688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
    Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
    Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of
    Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of
    Sasaki K; Uchikado Y; Okumura H; Omoto I; Kita Y; Arigami T; Uenosono Y; Owaki T; Maemura K; Natsugoe S
    Anticancer Res; 2017 Feb; 37(2):859-864. PubMed ID: 28179343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
    Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
    J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of
    Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
    J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
    Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of clinical and
    Marr L; Haller B; Pyka T; Peeken JC; Jesinghaus M; Scheidhauer K; Friess H; Combs SE; Münch S
    Sci Rep; 2022 May; 12(1):7148. PubMed ID: 35504955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
    Vollenbrock SE; Voncken FEM; Lambregts DMJ; Maas M; Donswijk ML; Vegt E; Ter Beek LC; van Dieren JM; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):176-185. PubMed ID: 32572560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
    Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy.
    Valkema MJ; de Lussanet de la Sablonière QG; Valkema R; Thomeer MGJ; Dwarkasing RS; Harteveld AA; Doukas M; Mostert B; van der Zijden CJ; van der Sluis PC; Lagarde SM; Wijnhoven BPL; Verburg FA; van Lanschot JJB
    Nucl Med Commun; 2024 Feb; 45(2):128-138. PubMed ID: 37982560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor SUVs on 18F-FDG PET/CT and Aggressive Pathological Features in Esophageal Squamous Cell Carcinoma.
    Lim CH; Park YJ; Shin M; Cho YS; Choi JY; Lee KH; Hyun SH
    Clin Nucl Med; 2020 Mar; 45(3):e128-e133. PubMed ID: 31977480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
    Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced Esophageal Squamous Cell Carcinoma treated with definitive chemoradiotherapy.
    Sakin A; Ozcelik M; Sahin S; Aydemir O; Aldemir MN; Iliklerden UH; Kotan MC
    Surg Oncol; 2022 Aug; 43():101809. PubMed ID: 35809492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
    Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of
    Valkema MJ; Noordman BJ; Wijnhoven BPL; Spaander MCW; Biermann K; Lagarde SM; Bennink RJ; Schreurs WMJ; Roef MJ; Hobbelink MGG; Janssen MJR; Graven LH; van Lanschot JJB; Valkema R
    J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.